PDS Biotechnology, a portfolio company of NetScientific, has submitted a Phase 3 protocol to the US Food and Drug Administration (FDA) for its VERSATILE-003 trial. The trial will evaluate the combination of PDS0101 and KEYTRUDA® in the treatment of recurrent or metastatic HPV16-positive head and neck cancer. The primary efficacy endpoint of the trial is overall survival. The Phase 3 study is expected to involve approximately 90-100 clinical sites globally and is anticipated to begin in Q4 2023. Interim data from the ongoing VERSATILE-002 Phase 2 trial have shown promising results.